// App-Quantinova.ai

1412 : Prediction of the treatment response to eribulin chemotherapy in breast cancer using tumor-infiltrating lymphocytes (TILs)

Researchers

Presenter

  • Kashiwagi Shinichiro

Principal Investigators

  • Yuka Asano

  • Wataru Goto

  • Kento Kurata

  • Tamami Morisaki

  • Satoru Noda

  • Tsutomu Takashima

  • Naoyoshi Onoda

  • Sayaka Tanaka

  • Masahiko Ohsawa

  • Masaichi Ohira

  • Kosei Hirakawa

Medical Centers

  • Osaka City Univ., Osaka, Japan.

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Eribulin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved